SR One Capital Management, LP
Top Portfolio Positions
14 positions ·
$914,169,725 total
· as of Mar 31, 2026
| Ticker | Company | Shares | Value (USD) | % of Portfolio | Open |
|---|---|---|---|---|---|
| ACLX |
Arcellx, Inc.
Healthcare
|
2,346,630 | $269,440,056 | 29.47% | |
| MANE |
Veradermics, Inc
Healthcare
|
2,401,868 | $151,677,964 | 16.59% | |
| ZBIO |
Zenas BioPharma, Inc.
Healthcare
|
5,037,854 | $98,490,045 | 10.77% | |
| CRSP |
CRISPR Therapeutics AG
Healthcare
|
2,038,763 | $96,983,955 | 10.61% | |
| DSGN |
Design Therapeutics, Inc.
Healthcare
|
6,526,476 | $69,441,704 | 7.60% | |
| ORIC |
Oric Pharmaceuticals, Inc.
Healthcare
|
4,514,929 | $57,204,150 | 6.26% | |
| ALMS |
Alumis Inc.
Healthcare
|
1,959,896 | $43,176,508 | 4.72% | |
| MLYS |
Mineralys Therapeutics, Inc.
Healthcare
|
1,563,966 | $42,367,838 | 4.63% | |
| SPRY |
ARS Pharmaceuticals, Inc.
Healthcare
|
4,012,903 | $32,223,611 | 3.52% | |
| ORKA |
Oruka Therapeutics, Inc.
Healthcare
|
430,330 | $21,107,686 | 2.31% |
Portfolio Trend
18 quarters · across all stocks
Holdings in ENGN
Shares Held
Position Value (USD)
8 quarters on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $5,092,177 | 747,750 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $6,752,182 | 747,750 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $5,107,132 | 747,750 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $2,721,810 | 747,750 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $3,349,920 | 747,750 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $4,972,537 | 747,750 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $4,935,150 | 747,750 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $4,715,000 | 500,000 | Shares | Sole | 2024-08-13 | |
| No 13F history on record for this holder in this stock. | ||||||